KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CareDx (CDNA) Cash from Financing Activities (2016 - 2025)

CareDx (CDNA) has disclosed Cash from Financing Activities for 13 consecutive years, with -$12.5 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 1280.07% to -$12.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$93.4 million through Dec 2025, down 1565.97% year-over-year, with the annual reading at -$93.4 million for FY2025, 1565.97% down from the prior year.
  • Cash from Financing Activities hit -$12.5 million in Q4 2025 for CareDx, up from -$26.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $189.2 million in Q1 2021 to a low of -$53.8 million in Q2 2025.
  • Historically, Cash from Financing Activities has averaged $2.6 million across 5 years, with a median of -$1.2 million in 2023.
  • Biggest five-year swings in Cash from Financing Activities: surged 25845.31% in 2021 and later plummeted 1962.03% in 2025.
  • Year by year, Cash from Financing Activities stood at -$834000.0 in 2021, then tumbled by 184.41% to -$2.4 million in 2022, then tumbled by 1033.09% to -$26.9 million in 2023, then skyrocketed by 96.64% to -$903000.0 in 2024, then tumbled by 1280.07% to -$12.5 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CDNA at -$12.5 million in Q4 2025, -$26.5 million in Q3 2025, and -$53.8 million in Q2 2025.